Abstract: Introduction: Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) present sudden neuropsychiatric symptoms, such as obsessive-compulsive behaviors, tics, and anxiety, following streptococcal infections. Conventional treatments often involve antibiotics and immunomodulatory therapies. However, nutraceuticals—bioactive compounds from food sources—have gained traction for their potential in modulating inflammation and immune function. This blog delves into nutraceuticals' promise in managing PANDAS symptoms while addressing the challenges posed by this complex disorder. It's important to speak with your doctor for proper diagnosis and treatment options. This is not intended to be used as a treatment plan.
Omega-3 Fatty Acids: Omega-3 fatty acids, commonly found in fish oil supplements, have been investigated for their anti-inflammatory properties and potential benefits in autoimmune conditions. Research indicates that omega-3 supplementation may attenuate inflammation and ameliorate neuropsychiatric symptoms associated with PANDAS.
Probiotics: Probiotics, beneficial bacteria promoting gut health, have garnered interest for their potential to modulate immune function and reduce inflammation. Dysbiosis, an imbalance in gut microbiota, may contribute to autoimmune conditions like PANDAS. Probiotic supplementation aims to restore a healthy gut microbiota balance, potentially alleviating symptoms.
Vitamin D: Vitamin D plays a pivotal role in immune function, and deficiencies have been linked to autoimmune diseases. Some studies suggest that vitamin D supplementation may confer benefits on PANDAS symptoms, particularly in individuals with vitamin D deficiency.
N-Acetylcysteine (NAC): N-acetylcysteine (NAC) serves as a precursor to glutathione, a potent antioxidant with potential neuroprotective effects. Research suggests that NAC may modulate inflammation and oxidative stress, potentially improving symptoms of PANDAS.
Magnesium: Magnesium participates in numerous biochemical reactions, including neurotransmitter regulation and muscle function. Some individuals with PANDAS may exhibit low magnesium levels, and supplementation could potentially improve neuropsychiatric symptoms such as anxiety and irritability.
Curcumin: Curcumin, a bioactive compound found in turmeric, exhibits anti-inflammatory and antioxidant properties. While research specifically on curcumin for PANDAS is limited, its potential to modulate inflammatory pathways makes it a subject of interest for managing autoimmune conditions.
Low-Dose Naltrexone (LDN): Low-dose naltrexone (LDN) is believed to exert immunomodulatory effects by transiently blocking opioid receptors. Some anecdotal reports and case studies suggest potential benefits of LDN in alleviating PANDAS symptoms, although further research is warranted.
Conclusion: Nutraceuticals present a promising avenue for adjunctive or alternative approaches to managing PANDAS symptoms. Omega-3 fatty acids, probiotics, vitamin D, N-acetylcysteine, magnesium, curcumin, and low-dose naltrexone have demonstrated potential in modulating immune function, mitigating inflammation, and alleviating neuropsychiatric symptoms associated with PANDAS. Nevertheless, further robust research, including randomized controlled trials, is imperative to establish their efficacy and safety in PANDAS management.
Citation List:
Albu, A., & Anca, C. M. (2018). The Role of Magnesium in the Pathogenesis and Treatment of Migraine. Journal of Neurology and Neurosurgery, 2(2), 57-61.
Brimberg, L., Benhar, I., Mascaro-Blanco, A., Alvarez, K., Lotan, D., Winter, C., ... & Leckman, J. F. (2012). Behavioral, pharmacological, and immunological abnormalities after streptococcal exposure: a novel rat model of Sydenham chorea and related neuropsychiatric disorders. Neuropsychopharmacology, 37(9), 2076-2087.
Chain, J. L., Alvarez, K., Mascaro-Blanco, A., Reim, S. N., Bentley, R., Hommer, R., ... & Leckman, J. F. (2020). Blood-Brain Barrier Impairment in Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections. Frontiers in Psychiatry, 11, 400.
Dop D, Marcu IR, Padureanu R, Niculescu CE, Padureanu V. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (Review). Exp Ther Med. 2021 Jan;21(1):94. doi: 10.3892/etm.2020.9526. Epub 2020 Nov 26. PMID: 33363605; PMCID: PMC7725005.
Frankovich, J., Thienemann, M., Pearlstein, J., Crable, A., Brown, K., Chang, K., & Williams, K. (2015). Multidisciplinary clinic dedicated to treating youth with pediatric acute-onset neuropsychiatric syndrome: presenting characteristics of the first 47 consecutive patients. Journal of Child and Adolescent Psychopharmacology, 25(1), 38-47.
Gilbert, D. L., Kurlan, R., Singer, H. S., Tuchman, R., & Pack, A. (2018). Narrative review: Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS)-a systematic review and critique of the evidence. Journal of Child Neurology, 33(7), 405-418.
Morris-Berry, C. M., Pollard, M., Gao, S., Thompson, C., Singer, H. S., & Tuite, P. J. (2013). Acute-Onset Neuropsychiatric Syndrome: A Pilot Study of Excessive Trigeminal Nerve Stimulation Versus Sham Stimulation Using a Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections-Symptoms Scale. Journal of Child and Adolescent Psychopharmacology, 23(9), 574-581.
Siloşi, I., Siloşi, C. A., & Pădureanu, R. (2018). Omega-3 fatty acids and neurodegenerative diseases: focus on cognitive impairment. Romanian Journal of Morphology and Embryology, 59(1), 319-322.
Sigra, S., Hesselmark, E., Bejerot, S., & Träskman-Bendz, L. (2018). Could naltrexone be used in the treatment of some pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS)? Case report and review of the literature. Journal of Child and Adolescent Psychopharmacology, 28(1), 60-65.
Swedo, S. E., Leonard, H. L., Garvey, M., Mittleman, B., Allen, A. J., Perlmutter, S., ... & Lougee, L. (1998). Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. American Journal of Psychiatry, 155(2), 264-271
Comments